

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA



MEDISTEP HEALTHCARE LIMITED

Corporate Identification Number: U21009GJ2023PLC141841

Our Company was originally incorporated on June 05, 2023 as 'Medistep Healthcare Limited', as a Public limited company under the Companies Act, 2013 bearing Corporate Identification Number U21009GJ2023PLC141841 pursuant to Certificate of Incorporation issued by Registrar of Companies, Ahmedabad. Thereafter our company acquired the business of Proprietorship Concern of one of our Promoter Mrs. Prajapati Hetalben Girdharilal viz, M/s MG Pharma through the business transfer agreement dated July 02, 2023. Subsequently the business of the sole proprietorship firm was transferred into Medistep Healthcare Limited For more details of Incorporation and Registered Office of our Company, please refer to chapter titled 'Our History and Certain Other Corporate Matters' on page no. 179 of the Prospectus.



(Please scan this QR code to view the webpage of the LM for viewing documents relating to the issue.)

Registered Office: 05, S. No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Nr. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmadabad City, Daskroi, Gujarat, India, 382405

CIN: U21009GJ2023PLC141841; Website: www.medistephc.com; E-Mail: info@medistephc.com

Company Secretary and Compliance Officer: Ms. Sashi Kala Bhutra; Telephone No.: +91 87808 46963

OUR PROMOTERS: MR. GIRDHARI LAL PRAJAPAT, MR. DABHI VIPUL GOBARBHA, MRS. PRAJAPATI HETALBEN GIRDHARILAL AND MR. JAGDISH PRAJAPATI

THE OFFER

INITIAL PUBLIC OFFERING OF UP TO 37,44,000 EQUITY SHARES OF Rs. 10/- EACH ("EQUITY SHARES") OF MEDISTEP HEALTHCARE LIMITED ("THE "COMPANY") FOR CASH AT A PRICE OF Rs. 43.00/- PER EQUITY SHARE (THE "ISSUE PRICE"), AGGREGATING TO Rs. 1609.92/- LAKH ("THE OFFER") OUT OF THE OFFER, 1,89,000 EQUITY SHARES AGGREGATING TO Rs. 81.27/- LAKH WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION I.E. OFFER OF 35,55,000 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- EACH AT AN ISSUE PRICE OF Rs. 43.00/- PER EQUITY SHARE AGGREGATING TO Rs. 1528.65/- LAKH IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 26.35% AND 25.02%, RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION

NOT APPLICABLE

FIXED PRICE ISSUE AT 43.00/- PER EQUITY SHARE OF FACE VALUE OF ₹ 10.00/- EACH.

THE ISSUE PRICE IS 4.3 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.

THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FISCAL 2024-25 AT THE ISSUE PRICE IS 10.72 TIMES.

BIDS CAN BE MADE FOR A MINIMUM OF TWO LOTS (LOT SIZE CONSIST OF 3000 EQUITY SHARES EACH) AND IN MULTIPLES OF 3000 EQUITY SHARES THEREAFTER.

BID/OFFER PERIOD

ISSUE OPENING DATE:
FRIDAY, AUGUST 08, 2025

ISSUE CLOSES ON:
TUESDAY, AUGUST 12, 2025

BRIEF DESCRIPTION OF THE BUSINESS OF THE ISSUER COMPANY:

The company operates in the pharmaceutical industry and is involved in the business of trading of pharmaceutical products, intimate care and hygiene products, surgical products & nutraceutical products and manufacturing of intimate and nutraceutical products. The company has strategically expanded its operations by acquiring the business of M/s MG Pharma, a proprietorship concern owned by one of our promoters, Ms. Prajapati Hetalben Girdharilal. This acquisition was executed through a business transfer agreement dated July 02, 2023. Following the agreement, the business of the sole proprietorship was integrated into Medistep Healthcare Limited. For detailed information please refer chapter titled "Our Business" on page no. 139 of the Prospectus.

"THE ISSUE IS BEING MADE PURSUANT TO CHAPTER IX (INITIAL PUBLIC OFFER BY SMALL AND MEDIUM ENTERPRISES) OF THE SEBI ICDR REGULATIONS, 2018 AMENDED FROM TIME TO TIME AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE") I.E. NSE EMERGE. NATIONAL STOCK EXCHANG OF INDIA SHALL BE THE DESIGNATED STOCK EXCHANGE." (For further details please see "The Issue" beginning on page no. 58 of the Prospectus.) A Copy of Prospectus is delivered for filing to the Registrar of Companies as required under sub-section 4 of Section 26 of the Companies Act, 2013.

ALLOCATION OF THE ISSUE

- Individual Investor who applies for minimum application size: 50.04% of the Net Issue
- Individual applicants who applies for minimum application size and other investors category: 49.96% of the Net Issue
- Market Maker: 5.05% of the Total Issue

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE PROSPECTUS AND THE TERMS OF THE OFFER, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE OFFER AVAILABLE IN ANY MANNER.

In accordance with the recommendation of the Independent Directors of our Company, pursuant to their resolution dated August 04, 2025 the above provided Issue Price is justified based on quantitative factors/ KPIs disclosed in the "Basis for Issue Price" section beginning on page no. 101 of the Prospectus vis-a-vis the weighted average cost of acquisition ("WACA") of primary and secondary transaction(s), as applicable, disclosed in "Basis for Issue Price" section beginning on page no.101 of the Prospectus and provided below in the advertisement.

RISKS TO INVESTORS

1. Risk to investors summary description of the key risk factors based on materiality:

The below mentioned risks are top 10 risk factors as per the Prospectus. (For further details on 'Risk Factors' please refer page no. 30 of the Prospectus, you can scan the QR code given on top of the advertisement for viewing Prospectus.)

- Expanding the company's business focus from trading pharmaceuticals to manufacturing sanitary pads, energy powders, and multivitamins introduces several inherent risk factors that must be carefully evaluated.
 - We provide our goods majorly in Gujarat, any adverse changes in the conditions affecting these regions can adversely affect our business, financial condition and results of operations.
 - We rely on domestic third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect our business, results of operations, financial condition and cash flows.
 - Our manufacturing facility are subject to operational risks. Any slowdown or shutdown in our manufacturing operations could adversely affect our business, financial condition and results of operations.
 - The Company is dependent on few numbers of customers for sales. The loss of any of this large customer may affect our revenues and profitability.
 - We are subject to extensive government regulations and if we fail to obtain, maintain or renew our statutory and regulatory licenses, permits and approvals required to operate our business, our business, financial condition, results of operations and cash flows may be adversely affected.
 - Any increase in the cost of our raw material or other purchases or a shortfall in the supply of our raw materials, may adversely affect the pricing and supply of our products and have an adverse effect on our business, results of operations and financial condition.
 - Our inability to successfully implement our business plan and growth strategy could have an adverse effect on our business, results of operations, financial condition and cash flows.
 - We have had negative cash flows from investing activities during the Financial Year 2024. Negative cash flows over extended periods, or significant negative cash flows in the short term, could affect our ability to operate our business and implement our growth plans.
 - We require working capital for our smooth day-to-day operations of business and any discontinuance or our inability to acquire adequate working capital timely and on favorable terms may have an adverse effect on our operations, profitability and growth prospects.
- Average Cost of Acquisition of Equity Shares held by the promoters is:

Name	Promoter / Promoter Group	No. of Shares held	Avg. Cost of Acquisition*(In Rs.)
Girdhari Lal Prajapat	Promoter	14,11,800	12.50
Dabhi Vipul Gobarbhai	Promoter	12,69,880	12.50
Prajapati Hetalben Girdharilal	Promoter	71,16,400	8.37
Jagdish Prajapati	Promoter	Nil	Nil

*Including the Equity Shares issued pursuant to bonus issue and transfer.

- The offer price is Rs. 43.00/- per Equity Share
- The Price-Earnings ratio based on diluted EPS for Fiscal 2025 for the Company is Rs. 10.72/-.
- Weighted Average Return on Net Worth for Fiscals 2025, 2024 and 2023 is 36.11%.

2. Details of suitable ratios of the company for the latest full financial year:

S. No.	Name of the Company	Face Value (Per Share)	CMP	EPS	P/E Ratio	RONW (%)	EBITDA	NAV (Rs. Per share)	PAT (Rs. in Lakh)
1	Medistep Healthcare Limited	10.00/-	43.00	4.01	10.72	24.62%	559.74	16.28	414.42
2	Fabino Enterprises Limited	10.00/-	26	0.63	41.27	3.12%	16.63	20.42	13.19
3	Achyut Healthcare Limited	1.00/-	4.18	0.02	209	1.77%	-20.20	1.33	54.77

*Source: <https://www.nseindia.com/> and <https://www.bseindia.com/>.

- Notes:**
 - Considering the nature and turnover of business of the Company the peer is not strictly comparable. However, the same have been included for broader comparison.
 - The figures for Medistep Healthcare Limited (Formerly named Medistep Healthcare Limited) are based on the restated results for financial year ended March 31, 2025.
 - The figures for the peer group are based on standalone audited results for the respective financial year ended March 31, 2025.
 - PE Ratio for peers is as per adjusted PE on the site of stock exchange as on 30th July, 2025.
 - Current Market Price (CMP) is the closing price of respective scrip as on 30th July, 2025.

For detailed information please refer chapter titled "Basis for Issue Price" on page no. 101 of the Prospectus

3. Weighted average return on net worth for the last 3 FYs, and return on net worth as per the restated financial statements:

S. No	Period	RoNW (%)	Weights
1.	Financial Year 2022-23	85.88	1
2.	Financial Year 2023-24	28.46	2
3.	Financial Year 2024-25	24.62	3
	Weighted Average	36.11%	

Note: i. The RoNW has been computed by dividing net profit after tax (excluding exceptional items) with restated Net worth as at the end of the year/ period
ii. Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNWxWeight) for each year / Total of weights

4. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI, as applicable.

- The price per share of our Company based on the primary/ new issue of shares (equity/convertible securities) Except as disclosed below, there has been no issuance of Equity Shares, other than Equity Shares issued pursuant to a Loan Conversion into Equity and Bonus Issue on 20.03.2024 and 12.04.2024 respectively, during the 18 months preceding the date of this Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days

Date of allotment	No. of equity allotted	Face Value of shares	Issue price per equity share (₹)	Nature of allotment	Nature of Consideration	Total Consideration (₹)
20.03.2024	29,39,440	10.00/-	25.00	Loan Conversion	Cash	7,34,86,000
12.04.2024	48,99,440	10.00/-	N.A.	Bonus	Other than Cash	N.A.
10.06.2024	6,66,666	10.00/-	15.00	Preferential Allotment	Cash	99,99,990

- The price per share of our Company based on the secondary sale / acquisition of shares (equity shares)
There has been no secondary sale / acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this certificate, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.
- Since there is eligible transaction reported under (a) above, the price per equity share of our Company based on last five primary and secondary transactions (secondary transactions where promoters, promoter group or shareholder(s) having the right to nominate director(s) on our Board, are a party to the transaction), not older than three years prior to the date of the Prospectus irrespective of the size of transactions, has not been computed.
- Weighted average cost of acquisition

Types of transactions	Weighted average cost of acquisition (₹)	Issue Price (i.e. ₹ 43.00)
Weighted average cost of acquisition of primary/new issue as per paragraph 8(a) above.	12.97	3.32

Weighted average cost of acquisition for secondary sale / acquisition as per paragraph 8(b) above.	NA*	NA*
Weighted average cost of acquisition for past 5 primary issuances/secondary transaction as disclosed above	NA	NA

Note: *There were no secondary sales/acquisition of shares of shares (equity/convertible securities) in last 18 months from the date of the Prospectus.

ADDITIONAL INFORMATION FOR INVESTORS:

Details of proposed / undertaken pre-issue placement from the filing date: Our Company has not undertaken any Pre-IPO Placements.

Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the Company by promoter(s) and promoter group(s) from the DP filing date:

Not Applicable

Shareholding of the Promoter/ Promoter Group and Additional Top 10 Shareholding of the Company:

Sr. No.	Name of Shareholder	Pre- Issue Shareholding as at the date of Advertisement		Post-Issue shareholding	
		Number of Equity Share (2)	Share Holding (in %) (2)	At the issue price (₹ 43.00/-)	
Promoters					
1.	Girdhari Lal Prajapat.	14,11,800	13.49%	14,11,800	9.94%
2.	Dabhi Vipul Gobarbhai	12,69,880	12.13%	12,69,880	8.94%
3.	Prajapati Hetalben Girdharilal	71,16,400	68.00%	71,16,400	50.08%
4.	Jagdish Prajapati	Nil	Nil	Nil	Nil
Total (A)		97,98,080	93.62%	97,98,080	68.96%
Promoter Group					
5.	Dabhi Dharmishtaben V	200	Negligible	200	Negligible
Total (B)		200	Negligible	200	Negligible
Additional Top 10 Shareholders					
6.	Ms. Nishakumari Vicky Agrawal	200	Negligible	200	Negligible
7.	SN Enterprise	6,66,666	6.37%	6,66,666	4.69%
8.	Mr. Agrawal Vicky Mahadev	200	Negligible	200	Negligible
9.	Mr. Vishnu Kumar	200	Negligible	200	Negligible
Total (C)		6,67,266	6.38%	6,67,266	4.70%
Total (A+B+C)		1,04,65,546	100%	1,04,65,546	73.65%

The shareholding of the company is held by the promoter, the promoter group and Four (4) other Public Shareholders, with no other individuals or entities holding any shares.

Notes:

- The Promoter Group shareholder is Dabhi Dharmishtaben V.
- Includes all options that have been exercised until date of Prospectus.
- Based on the Issue price of ₹ 43/- and subject to finalization of the basis of allotment.

Also, this table assumes there is no transfer of shares by these shareholders between the date of the advertisement and allotment.

BASIS FOR ISSUE PRICE

The "Basis of the issue price" on page no. 101 of the Offer document has been updated with the price. Please refer to the website of the LM i.e. https://www.ftnsec.com/resource/offer_documents/offer_documents.aspx for the "Basis of the issue price" updated with the price. You can scan the QR code mentioned on the Top of this advertisement for webpage of the LM where documents relating to the issue including the "Basis for Issue Price".

INDICATIVE TIMELINES FOR THE ISSUE

Sequence of Activities	Listing within T+3 days (T is Issue Closing Date i.e. Tuesday, August 12, 2025)
Application Submission by Investors	Electronic Applications (Online ASBA through 3-in-1 accounts) - Upto 4 pm on Tuesday, August 12, 2025. Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA etc.) - Upto 4 pm on Tuesday, August 12, 2025. Electronic Applications (Syndicate Non-Individual Applications) - Upto 4 pm on Tuesday, August 12, 2025. Physical Applications (Bank ASBA) - Upto 1 pm on Tuesday, August 12, 2025. Physical Applications (Syndicate Non-Individual Applications) - Upto 12 pm on Tuesday, August 12, 2025 and Syndicate members shall transfer such applications to banks before 1 pm on Tuesday, August 12, 2025.
Bid Modification	From Issue opening date up to 5 pm on Tuesday, August 12, 2025.
Validation of bid details with depositories	From Issue opening date up to 5 pm on Tuesday, August 12, 2025.
Reconciliation of UPI mandate transactions (Based on the guidelines issued by NPCI from time to time): Among Stock Exchanges- Sponsor Banks - NPCI and NPCI - PSPs/TPAPs** - Issuer Banks; Reporting formats of bid information, UPI analysis report and compliance timelines.	On daily basis transactions. Merchant Bankers to submit to SEBI, sought as and when.
UPI Mandate acceptance time	Tuesday, August 12, 2025- 5 pm
Issue Closure T day	Tuesday, August 12, 2025 - 4 pm for all categories
Third party check on UPI applications	On daily basis and to be completed before 9:30 PM on Tuesday, August 12, 2025.
Third party check on non-UPI applications	On daily basis and to be completed before 1 pm on Tuesday, August 12, 2025
Submission of final certificates: -For UPI from Sponsor Bank -For Bank ASBA, from all SCSBs -For syndicate ASBA UPI ASBA	Before 09:30 pm on Tuesday, August 12, 2025. All SCSBs for Direct ASBA - Before 07:30 pm on Tuesday, August 12, 2025. Syndicate ASBA - Before 07:30 pm on Tuesday, August 12, 2025.
Finalization of rejections and completion of basis	Before 6 pm on Wednesday, August 13, 2025
Approval of basis by Stock Exchange	Before 9 pm on Wednesday, August 13, 2025
Issuance of fund transfer instructions in separate files for debit and unblock. For Bank ASBA and Online ASBA - To all SCSBs For UPI ASBA - To Sponsor Bank	Initiation not later than 09:30 am on Thursday, August 14, 2025; Completion before 2 pm on Thursday, August 14, 2025 for fund transfer; Completion before 4 pm on Thursday, August 14, 2025 for unblocking.
Corporate action execution for credit of shares	Initiation before 2 pm on Thursday, August 14, 2025 Completion before 6 pm on Thursday, August 14, 2025
Filing of listing application with Stock Exchanges and issuance of trading notice	Before 7:30 pm on Thursday, August 14, 2025.
Publish allotment advertisement	On website of Issuer, Merchant Banker and RTI - before 9 pm on Monday, August 18, 2025. In newspapers - On Monday, August 18, 2025 day but not later than On Tuesday, August 19, 2025
Trading starts T+3 day	Trading starts Monday, August 18, 2025

** PSPs/TPAPs=Payment Service Providers/Third party application providers.

EVENT DETAILS

Event	Indicative Dates
Bid/ Issue Opening Date	Friday, August 08, 2025
Bid/ Issue Closing Date	Tuesday, August 12, 2025
Finalization of Basis of Allotment with the Designated Stock Exchange (T+1)	Wednesday, August 13, 2025
Initiation of Allotment/ Refunds/ Unblocking of Funds from ASBA Account or UPI Id Linked Bank Account (T+2)	Thursday, August 14, 2025
Credit of Equity Shares to Demat Accounts of Allottees (T+2)	Thursday, August 14, 2025
Commencement of Trading of The Equity Shares on the Stock Exchange (T+3)	Monday, August 18, 2025

ASBA*

Simple, Safe, Smart way of Application-make use of it.

*Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below.

Mandatory in Public issues from January 01, 2016. No Cheque will be accepted.

UPI – Now available in ASBA for individual investors and non-institutional investor applying for amount up to Rs. 5,00,000/- applying through Registered Brokers, DP's & RTAs. UPI Bidder also have the option to submit the Application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to that the Bank Account used for bidding is linked to their PAN. Bidders must ensure that their PAN ensure is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020, issued by the CBDT and the subsequent press release, including press release dated June 25, 2021 and September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press releases in this regard.

ASBA has to be availed by all the investors. UPI may be availed by (i) Individual Investors Portion. (ii) Non-Institutional Investors with an application size of up to Rs. 5,00,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section **"Issue Procedure"** on page no. 297 of the Prospectus. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of Stock Exchanges and can be obtained from the list of banks that is displayed on the website of SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35> and <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. ICICI Bank Limited has been appointed as Sponsor Banks for the Issue, in accordance with the requirements of the SEBI Circular dated November 1, 2018 as amended. For Issue related queries, please contact the BRLMs at their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll-free number: 18001201740 and mail Id: upi.npci@npci.org.in.

In case of any revisions in the Price, the Bid/ Issue Period will be extended by at least three additional Working Days after such revision of the Price, subject to the Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/Issue Period for a minimum one Working Day, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price and the revised Bid/Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the website of the Book Running Lead Managers and the terminals of the other members of the Syndicate and by intimation to SCSBs, the Sponsor Bank, Registered Brokers, Collecting Depository Participants and Registrar and Share Transfer Agents.

The Offer is being made through the Fixed Price Issue, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR") read with Regulation 252 of SEBI ICDR Regulations, 2018, the Offer is being made for at least 25% of the post-offer paid-up Equity Share capital of our Company. The Offer is being made under Regulation 229(2) of Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 via fixed issue process All Bidders For details, see "Issue Procedure" beginning on page no. 297 of the Prospectus.

Bidders/ Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidders/Applicants as available on the records of the Repositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to an Issue. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay reselling from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders/Applicants should ensure that PAN, DP ID and Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Investors must ensure that their PAN is linked with AADHAR and are in compliance with CBDT Notification dated February 13, 2020 and press release dated June 25, 2021.

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS: For information on the main objects and other objects of our Company, see **"Our History and Certain Corporate Matters"** on page no. 179 of the Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section **"Material Contracts and Documents for Inspection"** on page no. 339 of the Prospectus.

LIABILITY OF MEMBERS AS PER MOA: Limited by shares.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: As on the date of Prospectus, the Authorized share Capital of the Company is Rs. 15,00,00,000/- (Rupees Fifteen Crores Only) divided into 1,50,00,000 (One Crore and Fifty Lakhs Only) Equity Shares of face value of Rs.10/- each. The issued, subscribed and paid-up share capital of the Company before the issue Rs. 10,46,55,460.00/- (Rs. Ten Crores Forty-Six Lakhs and Fifty-Five Thousand Four Hundred and Sixty Only) divided into 1,04,65,546 (One Crore Four Lakhs Sixty-Five Thousand Five Hundred and Forty-Six Only). For details of the Capital Structure, see **"Capital Structure"** on the page no. 73 of the Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company, Ms. Nishakumari Vicky Agrawal- 100 equity shares, Ms. Dabhi Dharmistaben Y- 100 equity shares, Mr. Vishnu Kumar- 100 equity shares, Mr. Vicky Mahadev Agrawal- 100 equity shares, Mr. Dabhi Vipul Gobarabhai - 100 equity shares, Ms. Prajapati Hetalben Giridharlal - 9,400 equity shares and Mr. Giridharlal Prajapat - 100 equity shares of Rs.10/- each. Details of the main objects of the Company as contained in the Memorandum of Association, see **"History and Certain Corporate Matters"** on page no. 179 of the Prospectus. For details of the share capital and capital structure of the Company see **"History and Certain Corporate Matters"** on page no. 179 of the Prospectus.

LISTING: The Equity Shares offered through the Prospectus are proposed to be listed on the SME platform of NSE ("NSE Emerge"). Our Company has received an "In- principle" approval from the NSE for the listing of the Equity Shares pursuant to letter dated May 07, 2025. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of the Prospectus has been submitted for registration to the ROC on August 04, 2025 and Prospectus shall be filed with the RoC in accordance with Section 26(4) of the Companies Act, 2013.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, The Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page no. 276 of the Prospectus.


DISCLAIMER CLAUSE OF NSE ("NSE EMERGE") (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to the Offer Document for the full text of the Disclaimer Clause of NSE.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have

not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Prospectus. Specific attention of the investors is invited to **"Risk Factors"** on page no. 30 of the Prospectus.

TRACK RECORD OF LEAD MANAGER: The LM associated with the Issue has handled 11 Public Issues in the past three years out of which 3 issue was closed below the Issue/ Offer Price on listing date

Name of LM	Total Issue in last 3 years	Issue closed below IPO Price on listing date
Fast Track Finsec Private Limited	0	11
		3

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 Fasttrack Finsec Category-I Merchant Banker	 CAMEO	Ms. Sashi Kala Bhutra, Company Secretary & Compliance Officer Address: : 05, S- No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Nr. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmaddabad City, Daskroi, Gujarat, India, 382405 Tel.: +91 87808 46963 E-mail: info@medistephc.com Website: www.medistephc.com
FAST TRACK FINSEC PRIVATE LIMITED Address: Office No. V-116, 1 st Floor, New Delhi House, 27, Barakhamba Road, New Delhi – 110001 Tel: +91 11 43029809; Email: mb@ftfinsec.com Contact Person: Ms. Sakshi Website: www.ftfinsec.com SEBI registration number: INM000012500 CIN: U65191DL2010PTC200381	CAMEO CORPORATE SERVICES LIMITED Address: "Subramaniam Building", No. 1, Club House Road, Chennai-600002 SEBI Registration No.: INR000003753 Contact Person: Ms. K. Sreepriya Email: ipo@cameoindia.com Website: www.cameoindia.com Tel No: +91-44-40020700/28460390 CIN: U74899DL1995PTC071324	Investors can contact our Company Secretary and Compliance Officer, the Lead Manager or the Registrar to the Issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.
AVAILABILITY OF PROSPECTUS: Investors are advised to refer to the Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Prospectus is available on the website of the SEBI at www.sebi.gov.in , website of company at www.medistephc.com , the website of the Lead Manager to the Issue at www.ftfinsec.com , and websites of stock exchange at www.nseindia.com . AVAILABILITY OF THE ABRIDGED PROSPECTUS: A copy of the abridged prospectus shall be available on the website of the Company, LM and NSE at www.medistephc.com , www.ftfinsec.com and www.nseindia.com . AVAILABILITY OF BID-CUM-APPLICATI ON FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: Medistep Healthcare Limited (Telephone: 91 87808 46963) Lead Manager: Fast Track Finsec Private Limited (Telephone: +91-11-43029809). Bid-cum-application Forms will also be available on the website of NSE (www.nseindia.com) and the designated branches of SCSBs, the list of which is available at www.sebi.gov.in of the Stock Exchange and SEBI. SYNDICATE MEMBER: N.A. BANKER TO THE ISSUE/ ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: ICICI Bank Limited. SPONSOR BANKS: ICICI Bank Limited UPI: UPI Bidders can also Bid through UPI Mechanism. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus.		

Place: Ahmedabad

Date: August 04, 2025

Disclaimer: - Medistep Healthcare Limited proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares the Prospectus dated August 04, 2025 has been filed with the Registrar of Companies, Ahmedabad and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE Emerge at www.nseindia.com and is available on the websites of the LM at www.ftfinsec.com, Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

क्रॉसले रेमेडीज लिमिटेड

सीआईएन : U24239H2002PCL129635
पंजीकृत कार्यालय : मॅस हॉस्पिटल, गुरुग्राम, ब्लॉक बी, सुरांत लोक, फेज १, गुरुग्राम, हरयाणा, भारत - १२२ ००१

ई-मेल : secretarialcrl@maxhealthcare.com | सम्पर्क नं. +९१ ९८०३३३६६०

राष्ट्रीय कंपनी विधि न्यायाधिकरण, चंदीगढ़ बेंच, चंडीगढ़ के समक्ष
कंपनी कानून, २०१३ के खंड २३० से २३२ के मामले में और

क्रॉसले रेमेडीज लिमिटेड
(सीआईएन : U24239H2002PCL129635)
(याचिकाकर्ता कंपनी १/ हस्तांतरणकर्ता कंपनी) और

जयपी हेल्थकेअर लिमिटेड
(सीआईएन : U85191HR2012PCL129639)
(याचिकाकर्ता कंपनी २/ हस्तांतरित की कंपनी) और उनके संबंधित भागधारक एवं लेनदार

इन्के बीच
सी. पी. (सीएफ) नं. ३२/सीएचडी/एचआरआव/२०२५

सी.ए. (सीएफ) नं. २४/सीएचडी/एचआरआव/२०२५ से संबंधित

याचिका की सूचना

सूचना दी जा रही है कि, कंपनी कानून, २०१३ के खंड २३० से २३२ के तहत क्रॉसले रेमेडीज लिमिटेड ("याचिकाकर्ता कंपनी १/हस्तांतरक कंपनी") पंजीकृत कार्यालय का पता : मॅस हॉस्पिटल, गुरुग्राम, ब्लॉक बी, सुरांत लोक, फेज १, गुरुग्राम, हरयाणा - १२२ ००१ और जयपी हेल्थकेअर लिमिटेड ("याचिकाकर्ता कंपनी २/हस्तांतरित की कंपनी") पंजीकृत कार्यालय का पता : मॅस हॉस्पिटल, गुरुग्राम, ब्लॉक बी, सुरांत लोक, फेज १, गुरुग्राम, हरयाणा - १२२ ००१ एवं उनके संबंधित भागधारक एवं लेनदार (इसमें आगे याचिकाकर्ता कंपनी के तौर पर उल्लिखित) इनके बीच विलीनीकरण योजना की मंजूरी हेतु याचिकाकर्ता कंपनीयों द्वारा दि. ३१.०७.२०२५ को संयुक्त याचिका पेश की गई थी और यह याचिका सुनवाई हेतु समसामयिक राष्ट्रीय कंपनी विधि न्यायाधिकरण, चंदीगढ़ बेंच इनके समक्ष दि. १८.०९.२०२५ को निश्चित की गई है। इस याचिका को वदी आप विधिष करना इच्छुक हो तो आप याचिकाकर्ता के अधिकृत प्रतिनिधि के पास आकरके हेतु की सूचना आकरे और आकरे बिकल द्वा़र हस्ताक्षरित करते हुए इस सूचना के साथ, विरोध की पारमर्शपूर्ी एवं प्रतिज्ञापत्र की कापी इनके साथ याचिका की सुनवाई को निश्चित की गई तिथि से कमसे कम दो दिनों के भीतर पेश करें। यदि किसी व्यक्ति को याचिका की कापी आवश्यक हो तो उनके द्वारा लिए आवश्यक शुल्क प्रदान करने पर निम्न स्वाक्षरीकर्ता द्वारा पेश की जाएगी।

चंद्रशेखरन असोसिएट्स
(याचिकाकर्ता कंपनी १ के अधिकृत प्रतिनिधि)
११ - एफ, पॉकट - X, मयूर विहार,
फेज - १, नई दिल्ली- ११००११
दूरभाष नं : ०११-२२७०५५४४

फॉर्म-जी

एससीआर में रियल एस्टेट
में कार्यरत मलतीहार रियल्टर्स प्राइवेट लिमिटेड के लिए

रुचि की अपेक्षाविक्रय हेतु निमंत्रण

(भारतीय दिवाला और शोधन अक्षमता बोर्ड (कारपोरेट व्यक्तियों के लिए दिवाला प्रस्ताव प्रक्रिया) विनियमों, 2016 के नियम 36ए उअ विनियम (1) के अधीन)

संबंधित विवरण

क्र	क्रम	विवरण
1.	पैनालीआईएफएएलसी नंबर के साथ कारपोरेट डेनदार का नाम	कंपनी विवरण प्राइवेट लिमिटेड CIN: U70109DL2008PTC178745 PAN: AAFCONMS934K
2.	पंजीकृत कार्यालय का पता	पंजीकृत कार्यालय: 676, भुगत निवास गेट, चावडी बाजार, उत्तरी दिल्ली, दिल्ली, भारत-110006 https://corpmailna.in/
3.	वेबसाइट का यूआरएल	
4.	उप सूचन का विवरण जहां अधिकृत अचल संबंधित रिखा है:	कंपनी रिखा एस्टेट व्यवसाय में लगी हुई है और परियोजना यहां रिखा है: खस्ता रिखा 61/70,71,72,74 इन्फर्नोपूर गांव, सीनिया रिखा पूरुवा देह, लोदी, गांधीबाजार-20102 (ड्रैफ्टिंग रिडी के पास।)
5.	मुख्य उपनदीवेबआं की स्थापित क्षमता	परियोजना में परतइक्वायें ऑफिक रूप से निर्मित हैं, उपलब्ध जानकारी के अनुसार स्थापित कैपेटी की संख्या 220 है और सुविधाजनक दुकानें 5 दुकानें हैं।
6.	फिखल वित्तीय वर्ष में वेचे गए मुख्य उपनदीवेबआं की मात्रा और मुख्य	कंपनी रिखा एस्टेट के कारोबार में लगी हुई है और वर्तमान में उसके पास केवल एक परियोजना है जिसका नाम "ताज हाउटर्स" है, जो आंशिक रूप से निर्मित है और ऐसा लगता है कि निर्माण कार्य लगभग चार साल पहले बंद हो गया था।
7.	कागजात/कर्मचारियों की संख्या	दस्तावेज दस्तावेज
8.	दो वर्षों के अंतिम उपलब्ध वित्तीय विवरण (अनुसूची १ के तहत), ब्रह्मदाताओं की सूची सहित अन्य विवरण यहां अनुसंधान के उपलब्ध हैं।	वित्तीय वित्तीय
9.	कोड की पता 25(2)(एए) के अधीन प्रस्ताव आवेदन के लिए प्रस्ताव पर उपलब्ध हैं;	वित्तीय वित्तीय
10.	अतिरिचि की अपेक्षाविक्रय की प्राप्ति की अंतिम तिथि	25.08.2025
11.	प्रस्तावित प्रस्ताव आवेदनकों की अंतिम सूची जारी करने की तिथि	09.09.2025
12.	अंतिम सूची पर आगित्वी के प्रस्तुतिकरण की अंतिम तिथि	19.09.2025
13.	प्रस्तावित प्रस्ताव आवेदनकों को अंतिम सूची जारी करने की तिथि	24.09.2025
14.	प्रस्तावित आवेदनकों से सूचना प्राप्त, मूल्यांकन सारणी, प्रस्ताव बीजक हेतु अनुसंधान जारी करने की तिथि	24.10.2025
15.	प्रस्ताव बीजक के प्रस्तुत करने की अंतिम तिथि	24.10.2025
16.	अतिरिचि की अपेक्षाविक्रय प्रस्तुत करने की प्रक्रिया ईमेल आईडी	cirp.mallha@gmail.com
17.	एयरपोर्ट के रूप में कारपोरेट डेनदार को पंजीकृत रिडी का विवरण	कारपोरेट डेनदार सूचना, लघु और मध्यम व्यवसाय के साथ पंजीकृत है (उपम पंजीकरण संख्या उदा-यूडी-29-0146634)

ह./-
अनुराग निर्भय
प्रस्ताव प्रेषण
कृते मलतीहार रियल्टर्स प्राइवेट लिमिटेड

रजि. नं. IBBI/IPA-001/PI-P00870/2017-2018/11468
पंजीकृत पता: 204, सागर प्लाजा, प्लॉट नंबर 19, डिस्ट्रिक्ट सेंटर, लक्ष्मी नगर, नई दिल्ली-110092

दिनांक: 05.08.2025
स्थान: नई दिल्ली

प्रपत्र सं. 5
ऋण वसूली न्यायाधिकरण

600/1, यूनिवर्सिटी रोड, हुगुना सेतु मंदिर के निकट, लखनऊ-228007
(न्यायाधिकरण क्षेत्र : उत्तर प्रदेश का भाग)

उत्तर दाखिल करने तथा उत्तरदाित होने के लिए प्रकाशन द्वारा सम्मन
आए सं. 249/2025
पंजाब एंड सिंध बैंक
बनारस
श्री बनारस सिंह यादव एवं अन्य

सेवा में,
1. श्री बलराम सिंह यादव (कर्जदार) (वसूल्क) पुत्र श्री फूल चंद यादव, पता: प्लेट संख्या ए/ 904, गंगा तट, टावर-4, सेक्टर-1३7, यूनिवर्सिटी रोड, नोएडा, जी.डी. नगर, उत्तर प्रदेश-201301.

2. श्रीमती प्रीति यादव (सह-कर्जदार) (वसूल्क) पुत्री श्री बलराम सिंह यादव, पता: प्लेट संख्या ए/ 904, गंगा तट, टावर-4, सेक्टर-1३7, यूनिवर्सिटी रोड, नोएडा, जी.डी. नगर, यू.पी.-201301.

3. श्री योगेश राणा (गारंटर) (वसूल्क) पुत्र श्री सेखरच सिंह यादव : एफ-3१, एम.आई.सी. प्रताप विहार गाजियाबाद, उत्तर प्रदेश -201009

उपरोक्त आवेदन में आप से यह मांग की जाती है कि यह सम्मन प्रकाशित होने के बाद आप अपना उत्तर पेश कर चुक होंगे, दो सेट्स में, दस्तावेजों तथा सम्पत्तियों (यदि कोई हैं) सहित, उसकी प्रति आवेदक को अथवा उसके कानूनी सलाहकार/विधिवत अधिकृत एजेंट को भेजने के बाद, व्यक्तिगत रूप से या अपने विधिवत अधिकृत एजेंट या लीगल प्रैक्टिसर के माध्यम से प्रस्तुत करने के बाद इस न्यायाधिकरण में 11-09-2025 को पूर्ण, 10.30 बजे उपस्थित हों, जिसमें अस्मक वरने पर आवेदन की सुनवाई तथा निर्णय आपकी अनुपस्थिति में किया जाएगा।

रजिस्ट्रार
ऋण वसूली न्यायाधिकरण, लखनऊ

जयपी हेल्थकेअर लिमिटेड

सीआईएन : U85191HR2012PCL129639
पंजीकृत कार्यालय : मॅस हॉस्पिटल, गुरुग्राम, ब्लॉक बी, सुरांत लोक, फेज १, गुरुग्राम, हरयाणा, भारत - १२२ ००१

ई-मेल : secretarial@maxhealthcare.com | सम्पर्क नं. +९१ ९८०३३३६६०

राष्ट्रीय कंपनी विधि न्यायाधिकरण, चंदीगढ़ बेंच, चंडीगढ़ के समक्ष
कंपनी कानून, २०१३ के खंड २३० से २३२ के मामले में और

क्रॉसले रेमेडीज लिमिटेड
(सीआईएन : U24239H2002PCL129635)
(याचिकाकर्ता कंपनी १/ हस्तांतरणकर्ता कंपनी) और

जयपी हेल्थकेअर लिमिटेड
(सीआईएन : U85191HR2012PCL129639)
(याचिकाकर्ता कंपनी २/ हस्तांतरित की कंपनी) और उनके संबंधित भागधारक एवं लेनदार

इन्के बीच
सी. पी. (सीएफ) नं. ३२/सीएचडी/एचआरआव/२०२५

सी.ए. (सीएफ) नं. २४/सीएचडी/एचआरआव/२०२५ से संबंधित

याचिका की सूचना

सूचना दी जा रही है कि, कंपनी कानून, २०१३ के खंड २३० से २३२ के तहत क्रॉसले रेमेडीज लिमिटेड ("याचिकाकर्ता कंपनी १/हस्तांतरक कंपनी") पंजीकृत कार्यालय का पता : मॅस हॉस्पिटल, गुरुग्राम, ब्लॉक बी, सुरांत लोक, फेज १, गुरुग्राम, हरयाणा - १२२ ००१ और जयपी हेल्थकेअर लिमिटेड ("याचिकाकर्ता कंपनी २/हस्तांतरित की कंपनी") पंजीकृत कार्यालय का पता : मॅस हॉस्पिटल, गुरुग्राम, ब्लॉक बी, सुरांत लोक, फेज १, गुरुग्राम, हरयाणा - १२२ ००१ एवं उनके संबंधित भागधारक एवं लेनदार (इसमें आगे याचिकाकर्ता कंपनी के तौर पर उल्लिखित) इनके बीच विलीनीकरण योजना की मंजूरी हेतु याचिकाकर्ता कंपनीयों द्वारा दि. ३१.०७.२०२५ को संयुक्त याचिका पेश की गई थी और यह याचिका सुनवाई हेतु समसामयिक राष्ट्रीय कंपनी विधि न्यायाधिकरण, चंदीगढ़ बेंच इनके समक्ष दि. १८.०९.२०२५ को निश्चित की गई है। इस याचिका को वदी आप विधिष करना इच्छुक हो तो आप याचिकाकर्ता के अधिकृत प्रतिनिधि के पास आकरके हेतु की सूचना आकरे और आकरे बिकल द्वा़र हस्ताक्षरित करते हुए इस सूचना के साथ, विरोध की पारमर्शपूर्ी एवं प्रतिज्ञापत्र की कापी इनके साथ याचिका की सुनवाई को निश्चित की गई तिथि से कमसे कम दो दिनों के भीतर पेश करें। यदि किसी व्यक्ति को याचिका की कापी आवश्यक हो तो उनके द्वारा लिए आवश्यक शुल्क प्रदान करने पर निम्न स्वाक्षरीकर्ता द्वारा पेश की जाएगी।

चंद्रशेखरन असोसिएट्स
(याचिकाकर्ता कंपनी २ के अधिकृत प्रतिनिधि)
११ - एफ, पॉकट - X, मयूर विहार,
फेज - १, नई दिल्ली- ११००११
दूरभाष नं : ०११-२२७०५५४४

तिथि : ०५.०८.२०२५
स्थान : गुरुग्राम

जमना ऑटो इंडस्ट्रीज लिमिटेड

सीआईएन : L35911HR1965PLC004485

पंजीकृत कार्यालय: जय सिंग रोड, औद्योगिक क्षेत्र, यमुना नगर-135001, हरियाणा
कॉर्पोरेट कार्यालय: युनिट नं. 408, चौथी मंजिल, टावर-बी, वाटिका माइंडस्कैप, सेक्टर-27डी, एनएच2, फरीदाबाद-121003 (हरियाणा),

दूरभाष-0129-4006885 वेबसाइट: www.jaispring.com

ईमेल आईडी : investor.relations@jaispring.com

सूचना
आईडीपीएफ प्राधिकरण द्वारा बनाए गए निवेशक शिक्षा और संरक्षण कोष (आईडीपीएफ) डीमेट खाते में वित्तीय वर्ष 2017-18 (अंतिम) की गैर मुद्रास्व और दावा न की गई लाभांश राशि और कंपनी के इंडिकेटी शेयरों का हस्तांतरण।

एतद्वारा सूचित किया जाता है कि कंपनी अधिनियम, 2013 ("अधिनियम") की धारा 124(६) और (6) के साथ निवेशक शिक्षा और संरक्षण निधि प्राधिकरण (लेखा, लेखा परीक्षा, स्थानांतरण और वापसी) नियम, 2016 ("नियम") के नियम 5 और 6 के अनुसार, कंपनी को अनिवार्य रूप से सात वर्षों की अवधि के लिए दावा न किए गए या भुगतान न किए गए लाभांश को केंद्र सरकार द्वारा स्थापित निवेशक शिक्षा और संरक्षण निधि (आईडीपीएफ) में स्थानांतरित करना आवश्यक है।

कंपनी को ऐसे सभी शेयर भी आईडीपीएफ डीमेट खाते में स्थानांतरित करने होंगे, जिसके संबंध में शेयरधारकों द्वारा गुप्तगार सात वर्षों या उससे अधिक समय तक लाभांश का भुगतान या दावा नहीं किया गया है। आईडीपीएफ में स्थानांतरित होने के बाद, दावा न किए गए लाभांश राशि और शेयरों के संबंध में कंपनी को खिलाफ कोई दावा नहीं किया जाएगा।

तदनुसार, निम्नलिखित को आईडीपीएफ खाते में स्थानांतरित करने की आवश्यकता है:

स्थानांतरण का विवरण	की नियत तिथि	जाने वाली दावा करने की तिथि
दावारहित लाभार्थ वित्तीय वर्ष 2017-18 (अंतिम)	30 अक्टूबर, 2025	13 अक्टूबर, 2025 को या उससे पहले